This data de-risks the clinical path for zervimesine in a niche but severe indication with regulatory tailwinds (potential fast track/orphan designations). Traders should monitor for upcoming trial initiation, FDA feedback, and potential partnership or funding announcements. Given the $95M market cap, even modest clinical success could drive significant upside.
Price Chart
Executive Summary
Cognition Therapeutics presented Phase 2 SHIMMER study data showing zervimesine (CT1812) slowed decline in neuropsychiatric symptoms by 86% versus placebo in dementia with Lewy bodies (DLB). Based on these results and a recent FDA Type C meeting, the company plans to advance zervimesine into a late-stage trial for DLB psychosis, a high-unmet-need indication with no approved antipsychotics.
Key Facts
- Zervimesine demonstrated an 86% slowing of decline on the NPI-12 scale vs placebo in the Phase 2 SHIMMER study in DLB patients.
- The drug showed benefits across cognitive, motor, and global function domains, with a favorable safety profile in a population sensitive to traditional antipsychotics.
- Cognition plans a late-stage clinical trial for zervimesine in DLB psychosis, following a Type C meeting with the FDA.
- No currently approved antipsychotics exist for DLB due to severe safety risks; many traditional agents like haloperidol are contraindicated.
- Zervimesine is an oral, once-daily investigational therapy with a novel mechanism targeting toxic oligomers in neurodegenerative diseases.
Financial Impact
Potential for high commercial value given lack of approved treatments for DLB psychosis and large unmet need affecting up to 75% of DLB patients.
Risk Factors
- Phase 2 results may not replicate in larger, later-stage trials.
- Regulatory pathway for DLB psychosis remains undefined; FDA approval not guaranteed despite Type C meeting.
- High cash burn typical for clinical-stage biotechs; future dilution likely before commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers